CardioExchange Archive

November 16th, 2014

Prolonged Dual Antiplatelet Therapy Affirmed in DAPT

Larry Husten, PHD

The advent of drug-eluting stents dramatically reduced the restenosis rate associated with bare-metal stents but prompted new concerns about the rare but potentially lethal complication of stent thrombosis (ST). Cardiologists have relied upon dual antiplatelet therapy to prevent ST but there has been considerable uncertainty and controversy about the ideal duration of therapy. The Dual Antiplatelet […]

---

July 21st, 2014

Selections from Richard Lehman’s Literature Review: July 21st

Richard Lehman, BM, BCh, MRCGP

This week’s topics include the effects of extended-release niacin with laropiprant in high-risk patients and dual-antiplatelet beyond one year after DES implantation.

---

June 30th, 2014

Registry Study Offers Reassurance About Newer Drug-Eluting Stents

Larry Husten, PHD

Findings from a large ongoing registry study provide some reassurance about the long-term safety of new-generation drug-eluting stents (DES)  in patients with STEMI who undergo primary PCI. The results are published online in the Journal of the American College of Cardiology. SCAAR (Swedish Coronary Angiography and Angioplasty Registry) investigators analyzed data from 34,000 primary PCI patients who […]

---

December 9th, 2013

Selections from Richard Lehman’s Literature Review: December 9th

Richard Lehman, BM, BCh, MRCGP

This week’s topics include targeted temperature management after cardiac arrest, the safety and efficacy of DES in women, and more.

---

October 31st, 2013

Does OPTIMIZE Reveal the Optimal DAPT Time Frame?

Richard A. Lange, MD, MBA and L. David Hillis, MD

Rick Lange and David Hillis pose several important questions triggered by the OPTIMIZE findings.

---

October 21st, 2013

Refining the Optimal Duration of Dual Antiplatelet Therapy After DES Implantation

Cheol-Whan Lee, MD and Seung-Jung Park, MD.,Ph.D

Cheol Whan Lee and Seung-Jung Park discuss their study group’s randomized trial comparing dual antiplatelet therapy with aspirin alone beyond 12 months after drug-eluting stent implantation.

---

January 21st, 2013

Selections from Richard Lehman’s Literature Review: January 21st

Richard Lehman, BM, BCh, MRCGP

This week’s topics include a review of drug-eluting stents and a summary of hypertrophic cardiomyopathy.

---

November 15th, 2012

FDA Approves Zilver PTX Drug-Eluting Stent for Peripheral Arterial Disease

Larry Husten, PHD

The FDA today approved Cook Medical’s Zilver PTX stent. It is the first drug-eluting stent (DES) approved for the treatment of peripheral arterial disease (PAD) in the superficial femoral and proximal (i.e., above the knee) popliteal artery. The new stent will provide a new treatment option for patients with PAD. Current treatments include exercise, drug […]

---

September 19th, 2012

Stopping DAPT for DES Before 12 Months: Cutting-Edge or Dangerous?

Deepak L. Bhatt, MD, MPH, Richard A. Lange, MD, MBA and L. David Hillis, MD

Dr. Deepak Bhatt ponders the clinical implications of two studies suggesting that early discontinuation of dual antiplatelet therapy is safe — and concludes that the findings will probably not change his practice.

---

September 4th, 2012

You Got the Criminal. But What About the Bystander?

Mark Dayer, MD PhD FRCP and James Fang, MD

A drug-eluting stent is successfully implanted after an acute inferior MI in a fit 70-year-old man. What do you do for the bystander disease detected at the LAD/D1 junction?

---